Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Brief Summary: This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).


Options:
A: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 3.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 3.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 4.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 4.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg | Intervention Type: DRUG; Name: Ofatumumab 3mg; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.2, Cohort 4.2, Cohort 5.2 | Intervention Type: DRUG; Name: Ofatumumab 30mg; Assigned to Arm(s): Cohort 3.1, Cohort 3.2 | Intervention Type: DRUG; Name: Ofatumumab 60mg; Assigned to Arm(s): Cohort 4.1, Cohort 4.2, Cohort 5.1, Cohort 5.2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.1, Cohort 3.2, Cohort 4.1, Cohort 4.2, Cohort 5.1
C: Arm Label: Placebo-Controlled Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Active Treatment Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Off Drug; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Active Treatment Phase: Laquinimod 1.2 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 1.2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Placebo
D: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo

Answer: C